Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Shu, Yongqian ^a   Wu, Xue ^b   Tong, Xiaoling ^b   Wang, Xiaonan ^c   Chang, Zhili ^c   Mao, Yu ^c   Chen, Xiaofeng ^a   Sun, Jing ^a   Wang, Zhenxin ^d   Hong, Zhuan ^e   Zhu, Liangjun ^e   Zhu, Chunrong ^d   Chen, Jun ^f   Liang, Ying ^g   Shao, Huawu ^c,h   Shao, Yang W ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Geneseeq Technology Inc   (Canada)

^c Geneseeq Technology Inc   (China)

^d SOOCHOW UNIVERSITY   (China)

^e JIANGSU CANCER HOSPITAL   (China)

^f NINGBO UNIVERSITY   (China)

^g SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^h CHENGDU INSTITUTE OF BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; TUMOR MARKER;

CLINICAL DECISION MAKING; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MULTICENTER STUDY; MUTATION; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES; WORKFLOW;

BIOMARKERS, TUMOR; CIRCULATING TUMOR DNA; CLINICAL DECISION-MAKING; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; PRECISION MEDICINE; WORKFLOW;

EID: 85017130888     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-00520-1     Document Type: Article

References (55)

1. Lengauer, C., Kinzler, K. W., Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-649, doi:10. 1038/25292 (1998).
2. Meacham, C. E., Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-337, doi:10. 1038/nature12624 (2013).
3. Banerjee, S., Kaye, S. The role of targeted therapy in ovarian cancer. European journal of cancer 47 (Suppl 3), S116-S130, doi:10. 1016/S0959-8049(11)70155-1 (2011).
4. Roychowdhury, S., et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Science translational medicine 3, 111ra121, doi:10. 1126/scitranslmed. 3003161 (2011).
5. Craig, D. W., et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Molecular cancer therapeutics 12, 104-116, doi:10. 1158/1535-7163. MCT-12-0781 (2013).
6. Ding, L., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005, doi:10. 1038/nature08989 (2010).
7. Frampton, G. M., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature biotechnology 31, 1023-1031, doi:10. 1038/nbt. 2696 (2013).
8. Shyamala, K., Girish, H. C., Murgod, S. Risk of tumor cell seeding through biopsy and aspiration cytology. Journal of International Society of Preventive, Community Dentistry 4, 5-11, doi:10. 4103/2231-0762. 129446 (2014).
9. Qi, J., et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer research 71, 1081-1091, doi:10. 1158/0008-5472. CAN-10-1623 (2011).
10. Misale, S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536, doi:10. 1038/nature11156 (2012).
11. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
12. Amir, E., et al. Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clinical oncology 20, 763-768, doi:10. 1016/j. clon. 2008. 08. 005 (2008).
13. Gerlinger, M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine 366, 883-892, doi:10. 1056/NEJMoa1113205 (2012).
14. Jahr, S., et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer research 61, 1659-1665 (2001).
15. Jiang, P., et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America 112, E1317-E1325, doi:10. 1073/pnas. 1500076112 (2015).
16. Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M., Shendure, J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell 164, 57-68, doi:10. 1016/j. cell. 2015. 11. 050 (2016).
17. Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A., Anker, P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clinica chimica acta; international journal of clinical chemistry 313, 139-142 (2001).
18. Yu, S. C., et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clinical chemistry 59, 1228-1237, doi:10. 1373/clinchem. 2013. 203679 (2013).
19. Minchin, R. F., Carpenter, D., Orr, R. J. Polyinosinic acid and polycationic liposomes attenuate the hepatic clearance of circulating plasmid DNA. The Journal of pharmacology and experimental therapeutics 296, 1006-1012 (2001).
20. Lo, Y. M., et al. Rapid clearance of fetal DNA from maternal plasma. American journal of human genetics 64, 218-224, doi:10. 1086/302205 (1999).
21. Thierry, A. R., et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nature medicine 20, 430-435, doi:10. 1038/nm. 3511 (2014).
22. Freidin, M. B., et al. Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies. Clinical chemistry 61, 1299-1304, doi:10. 1373/clinchem. 2015. 242453 (2015).
23. Diehl, F., et al. Circulating mutant DNA to assess tumor dynamics. Nature medicine 14, 985-990, doi:10. 1038/nm. 1789 (2008).
24. Bettegowda, C., et al. Detection of circulating tumor DNA in early-A nd late-stage human malignancies. Science translational medicine 6, 224ra224, doi:10. 1126/scitranslmed. 3007094 (2014).
25. Murtaza, M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112, doi:10. 1038/nature12065 (2013).
26. Newman, A. M., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine 20, 548-554, doi:10. 1038/nm. 3519 (2014).
27. Sausen, M., et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature communications 6, 7686, doi:10. 1038/ncomms8686 (2015).
28. Leary, R. J., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Science translational medicine 4, 162ra154, doi:10. 1126/scitranslmed. 3004742 (2012).
29. Chen, W., Zheng, R., Zeng, H., Zhang, S. Epidemiology of lung cancer in China. Thoracic cancer 6, 209-215, doi:10. 1111/1759-7714. 12169 (2015).
30. Zhou, C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology 12, 735-742, doi:10. 1016/S1470-2045(11)70184-X (2011).
31. Herbst, R. S., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODiAC): A double-blind, randomised, phase 3 trial. The Lancet. Oncology 11, 619-626, doi:10. 1016/S1470-2045(10)70132-7 (2010).
32. Shaw, A. T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England journal of medicine 368, 2385-2394, doi:10. 1056/NEJMoa1214886 (2013).
33. Zhao, M., Wang, Q., Wang, Q., Jia, P., Zhao, Z. Computational tools for copy number variation (CNV) detection using nextgeneration sequencing data: Features and perspectives. BMC Bioinformatics 14 (Suppl 11), S1, doi:10. 1186/1471-2105-14-S11-S1 (2013).
34. Wagle, N., et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer discovery 2, 82-93, doi:10. 1158/2159-8290. CD-11-0184 (2012).
35. Ma, C., Wei, S., Song, Y. T790M and acquired resistance of EGFR TKI: A literature review of clinical reports. J Thorac Dis 3, 10-18, doi:10. 3978/j. issn. 2072-1439. 2010. 12. 02 (2011).
36. Thress, K. S., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nature medicine 21, 560-562, doi:10. 1038/nm. 3854 (2015).
37. Pao, W., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine 2, e17, doi:10. 1371/journal. pmed. 0020017 (2005).
38. Cancer Genome Atlas Research, N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525, doi:10. 1038/nature11404 (2012).
39. Diehl, F., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proceedings of the National Academy of Sciences of the United States of America 102, 16368-16373, doi:10. 1073/pnas. 0507904102 (2005).
40. Minoche, A. E., Dohm, J. C., Himmelbauer, H. Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol 12, R112, doi:10. 1186/gb-2011-12-11-r112 (2011).
41. Lanman, R. B., et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PloS one 10, e0140712, doi:10. 1371/journal. pone. 0140712 (2015).
42. Newman, A. M., et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature biotechnology 34, 547-555, doi:10. 1038/nbt. 3520 (2016).
43. Kandioler, D., et al. TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients. EBioMedicine 2, 823-828, doi:10. 1016/j. ebiom. 2015. 06. 003 (2015).
44. Knudsen, E. S., Wang, J. Y. Targeting the RB-pathway in cancer therapy. Clinical cancer research: An official journal of the American Association for Cancer Research 16, 1094-1099, doi:10. 1158/1078-0432. CCR-09-0787 (2010).
45. James, C. R., Quinn, J. E., Mullan, P. B., Johnston, P. G., Harkin, D. P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. The oncologist 12, 142-150, doi:10. 1634/theoncologist. 12-2-142 (2007).
46. Li, S., et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: A comprehensive mutation profiling from 5125 Chinese cohorts. British journal of cancer 110, 2812-2820, doi:10. 1038/bjc. 2014. 210 (2014).
47. Shi, Y., et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology: Official publication of the International Association for the Study of Lung Cancer 9, 154-162, doi:10. 1097/JTO. 0000000000000033 (2014).
48. Bolger, A. M., Lohse, M., Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114-2120, doi:10. 1093/bioinformatics/btu170 (2014).
49. Li, H., Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760, doi:10. 1093/bioinformatics/btp324 (2009).
50. DePristo, M. A., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics 43, 491-498, doi:10. 1038/ng. 806 (2011).
51. Koboldt, D. C., et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome research 22, 568-576, doi:10. 1101/gr. 129684. 111 (2012).
52. Wang, K., Li, M., Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research 38, e164, doi:10. 1093/nar/gkq603 (2010).
53. Newman, A. M., et al. FACTERA: A practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics 30, 3390-3393, doi:10. 1093/bioinformatics/btu549 (2014).
54. Amarasinghe, K. C., et al. Inferring copy number and genotype in tumour exome data. BMC genomics 15, 732, doi:10. 1186/1471-2164-15-732 (2014).
55. Meric-Bernstam, F., et al. A decision support framework for genomically informed investigational cancer therapy. Journal of the National Cancer Institute 107, doi:10. 1093/jnci/djv098 (2015).